Merck's Valuation Soars into Overbought Territory
Merck & Company, Inc. (MRK) has seen its valuation become extremely rich after a +92% total return since June 2025.
The company's stock has been driven into overbought territory due to investor enthusiasm for the Moderna mRNA melanoma vaccine collaboration.
Analyst Tolikoff recommends selling MRK or avoiding new positions until a 15-25% correction materializes, targeting a $110, $125 price range by early 2027.